Countries Australia

Neuren Pharmaceuticals Announces Positive Phase 2 Trial Results for NNZ-2591 in Pitt Hopkins Syndrome

Neuren Pharmaceuticals revealed top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS). This trial demo...

 May 28, 2024 | News

Telix Pharmaceuticals Submits NDA for Innovative Prostate Cancer Imaging Kit to FDA

Telix Pharmaceuticals  announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA...

 May 27, 2024 | News

Envac Wins €10 Million Contracts to Enhance Waste Management in French Hospitals

Smart waste management in hospitals has been increasingly important for achieving the higher standards of safety and environmental expectation required by ...

 May 22, 2024 | News

BeiGene and Glenmark Forge Strategic Partnership to Distribute Innovative Cancer Treatments in India

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced a new partnership with Glenmark Specialty S.A. (Glen...

 May 21, 2024 | News

Telix Pharmaceuticals' CUPID Study Demonstrates Promising Results for Next-Generation Prostate Cancer Therapy

CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based targeted alpha therapy for prostate cancer. Establishes ...

 May 21, 2024 | News

Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia

    “Approval of the Axonics recharge-free system is welcome news for Australians with bladder and bowel dysfunction,” said...

 May 17, 2024 | News

NeuShen Therapeutics Begins Phase I Trial of NS-136, a Potential Breakthrough in Schizophrenia Treatment

NeuShen Therapeutics , a clinical-stage global biotechnology company dedicated to pioneering treatments for neurological and psychiatric disorders, today a...

 May 10, 2024 | News

Avance Clinical Expands Further into APAC with New Clinical Operations in South Korea

Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, will attend BIO Korea (May 8-10, 2024) and formally open ...

 May 08, 2024 | News

Alnylam and Medison Expand Global Partnership to Accelerate Access to Innovative Therapies

  The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one glo...

 May 01, 2024 | News

FDA Approves Ractigen Therapeutics' IND for Groundbreaking Bladder Cancer Therapy

Ractigen Therapeutics, a leader in the development of small activating RNA (saRNA) therapeutics, announced today that the U.S. Food and Drug Administration...

 April 29, 2024 | News

Western Australia Boosts Biomedical Sector with Additional Funding for MTPConnect Training Programs

MTPConnect welcomes additional funding from the Western Australian Government to deliver critical industry training programs to boost the state’s bio...

 April 22, 2024 | News

Actinogen Medical Launches Phase 2b XanaMIA Trial for Alzheimer's, Marks First Patient Treatment

Actinogen Medical Limited (ASX: ACW) announces that the first patient has been randomized and treated in the XanaMIA phase 2b clin...

 April 16, 2024 | News

Cure Brain Cancer Foundation Launches Pioneering $575,000 Fellowship to Support Emerging Leaders in Brain Cancer Research

Cure Brain Cancer Foundation proudly unveiled the launch of its groundbreaking 5-Year Guardian Trust Early Career Fellowship, valued at $575,000. The...

 April 08, 2024 | News

Ractigen Therapeutics Launches Pioneering Phase I Clinical Trial for Bladder Cancer with First Patient Dosed in Collaboration with GenesisCare

Ractigen Therapeutics, a pioneer in small activating RNA (saRNA) therapeutics, achieved a major milestone with the first patient dosed in its First-in-huma...

 April 04, 2024 | News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in